Investment Thesis
Sonoma Pharmaceuticals faces critical financial distress with stagnant revenue, persistent operating losses, and unsustainable cash burn depleting its $2.6M reserve in less than one year. Despite adequate liquidity ratios and minimal debt, the deteriorating net income (-18.8% YoY) and negative returns (ROE -75.6%, ROA -19.0%) signal structural unprofitability with no visible path to operational sustainability.
Strengths
- Strong current ratio (2.88x) and quick ratio (2.00x) provide near-term liquidity buffer
- Low debt burden (0.00x debt/equity ratio) minimizes solvency risk from leverage
- Decent gross margin (37.5%) indicates some revenue generation capability and pricing power
Risks
- Stagnant revenue at $14.0M with 0% YoY growth shows no business momentum or market traction
- Operating cash flow of -$3.4M against only $2.6M cash reserves creates sub-one-year solvency window
- Deteriorating profitability with net income down 18.8% YoY and negative operating margin of -15.1%
- Return metrics deeply negative (ROE -75.6%, ROA -19.0%) indicating value destruction
- Zero insider Form 4 filings in 90 days suggests lack of management confidence in recovery
Key Metrics to Watch
- Operating cash flow trajectory - current -$3.4M burn rate determines survival timeline
- Revenue growth rate - company requires immediate top-line acceleration to achieve profitability
- Cash position depletion - critical threshold approaching with <$2.6M reserves and continuing losses
Financial Metrics
Revenue
14.0M
Net Income
-2.6M
EPS (Diluted)
$-1.56
Free Cash Flow
-3.6M
Total Assets
13.6M
Cash
2.6M
Profitability Ratios
Gross Margin
37.5%
Operating Margin
-15.1%
Net Margin
-18.6%
ROE
-75.6%
ROA
-19.0%
FCF Margin
-25.6%
Balance Sheet & Liquidity
Current Ratio
2.88x
Quick Ratio
2.00x
Debt/Equity
0.00x
Debt/Assets
74.8%
Interest Coverage
-2,110.00x
Long-term Debt
15.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-16T06:09:25.182542 |
Data as of: 2025-12-31 |
Powered by Claude AI